Safety and Dosing of Lutetium-PSMA in the Pre-Chemotherapy PSMAfore Trial - Oliver Sartor
Oliver Sartor
Zachary Klaassen speaks with Oliver Sartor about safety and dosing in the PSMAfore trial examining lutetium PSMA-617 in metastatic castration-resistant prostate cancer.